Modulating Intracellular Dynamics for Optimized Intracellular Release and Transcytosis Equilibrium

Area of Science:

• Nanomedicine
• Biotechnology
• Oncology

Background:

• Active transcytosis is crucial for nanomedicine delivery to tumors, but balancing intracellular drug release and tumor penetration remains a challenge.
• Optimizing nanomedicine design requires understanding subcellular distribution and transport mechanisms for effective cancer therapy.

Purpose of the Study:

• To design and screen polyglutamine-paclitaxel conjugates (OPGA-PTX) with varying hydrophilic/hydrophobic ratios (HHR) and tertiary amine-oxide proportions (TP).
• To identify a nanomedicine candidate that optimizes transcytosis for tumor penetration and intracellular release for enhanced anticancer efficacy.

Main Methods:

• Synthesized a series of OPGA-PTX conjugates with systematically varied HHR and TP.
• Evaluated cellular uptake, subcellular localization, transcytosis capability, and tumor penetration of the conjugates.
• Identified the optimal candidate (OPPX) based on its trafficking pathways and drug release profile.

Main Results:

• Identified OPPX (HHR 10:1, TP 100%) as a superior nanomedicine candidate.
• OPPX exhibits rapid internalization via multiple endocytic pathways.
• OPPX traffics to the Golgi for transcytosis and to lysosomes for cathepsin B-activated drug release, facilitating tumor accumulation and penetration.

Conclusions:

• Modulating nanomedicine subcellular distribution is a viable strategy to enhance active transport and intracellular release.
• OPPX serves as an exemplary nanomedicine for efficient anticancer drug delivery.
• This approach offers a new paradigm for designing effective anticancer nanomedicines.